Please assess the completion status of the following clinical trial:

Trial Title: Micafungin Lock Therapy

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE1
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Children, 6 months-18 yrs, with a central line fungal infection, presumed Candida, admitted at Children's Medical Center.~* Signed informed consent by parents and assent by minor if applicable.~* Subjects with likely survival beyond 1 week.~Exclusion Criteria:~* Pocket, tunnel or exit-site infection~* Known allergic reactions to the Micafungin or echinocandins.~* Severe systemic symptoms (disseminated candidemia, fungal balls, endocarditis)~* Mixed infections~* Inability to lock the catheter lumen for minimum 8h because of other medications administration~* Subjects requiring ECMO or CVVH.~* Patients with HIV, congenital immunodeficiencies.~* Positive pregnancy test or breastfeeding.

- Gender: ALL
- Minimum Age: 6 Months
- Maximum Age: 18 Years
- Healthy Volunteers: f

Study Arms:
- 1 (Type: PLACEBO_COMPARATOR): ALT with placebo with systemic Micafungin therapy
- 2 (Type: EXPERIMENTAL): ALT with Micafungin and heparin with systemic Micafungin therapy

Based on this trial design, predict the completion outcome and termination type (if applicable).